[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368654-105":59,"doc-detail-368654-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immunodiagnostic-plasma-amino-acid-residue-biomarkers-detect-cancer-early-and-predict-treatment-response","Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response","","Immunodiagnostic platform based on cancer-specific immune activation is developed using a panel of amino acid residue biomarkers measurable optically in neat blood plasma. Total concentrations of cysteine, free cysteine, lysine, tryptophan, and tyrosine are quantified and interpreted with supervised machine learning. In validation with 170 participants, 78% of cancers are detected with 0% false positives (AUROC 0.95), and biomarker patterns differ from autoimmune and infectious diseases. Concentration ranges further predict response to cyclin-dependent kinase inhibitors in advanced breast cancer, identifying 98% of responders (p \u003C 0.05).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immunodiagnostic-plasma-amino-acid-residue-biomarkers-detect-cancer-early-and-predict-treatment-response/368654/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immunodiagnostic-plasma-amino-acid-residue-biomarkers-detect-cancer-early-and-predict-treatment-response/368654.png","ImageObject",300,407,{"name":92,"@type":93},"Đào","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-18","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What biomarkers are used in the immunodiagnostic platform?","Question",{"text":112,"@type":113},"The study measures total concentrations of cysteine and free cysteine, as well as lysine, tryptophan, and tyrosine, which act as protein-incorporated biomarkers reflecting cancer-specific immune activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How well does the platform detect early cancer?",{"text":117,"@type":113},"In a validation set of N = 170, the model identifies 78% of cancers with 0% false positives (N = 97) and reports an AUROC of 0.95.",{"name":119,"@type":110,"acceptedAnswer":120},"Can the biomarkers predict treatment response?",{"text":121,"@type":113},"Yes. Specific concentration ranges predict response to cyclin-dependent kinase inhibitors in advanced breast cancer patients, identifying 98% of responders (N = 33) with p \u003C 0.05.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368654,1790260403,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374402968488,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article [https://doi.org/10.1038/s41467-025-61685-2](https://doi.org/10.1038/s41467-025-61685-2)  \nImmunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response  \nReceived: 7 August 2024  \n\n| Accepted: 25 June 2025 |\n| --- |\n| |\n| Check for updates |\n\nCong Tang 1,2,3 , Patrícia Corredeira1, Sandra Casimiro 1, Qi Shi4,  \nQiwei Han 4, Wesley Sukdao2, Ana Cavaco1, Cecília Melo-Alvim5,  \nCarolina Ochôa Matos6,7, Catarina Abreu5, Steven Walsh2,  \nGonçalo Nogueira-Costa5, Leonor Ribeiro5, Rita Sousa5, Ana Lorena Barradas 1, João Eurico Fonseca6,7, Luís Costa 1,5 , Emma V. Yates 2  &  \nGonçalo J. L. Bernardes 1,8,9   \nThe immune response to tumour development is frequently targeted with therapeutics but remains largely unexplored in diagnostics, despite being stronger for early-stage tumours. We present an immunodiagnostic platform to detect this. We identify a panel of amino acid residue biomarkers providing a signature of cancer-speciﬁc immune activation associated with tumour development and distinct from autoimmune and infectious diseases, measurable optically in neat blood plasma, and validate within N = 170 participants. By measuring the total concentrations of cysteine, free cysteine, lysine, tryptophan, and tyrosine protein-incorporated biomarkers and analyzing the results with supervised machine learning, we identify 78% of cancers with 0% false positive rate (N = 97) with an AUROC of 0.95. The cancer, healthy, and autoimmune/infectious biomarker pattern are statistically signiﬁcantly different (p \u003C 0.0001). Smaller-scale changes in biomarker concentrations reveal inter-patient differences in immune activation that predict treatment response. Speciﬁc concentration ranges of these biomarkers predict response to Cyclin-dependent kinase inhibitors in advanced breast cancer patients (p \u003C 0.05), identifying 98% of responders (N = 33). Here we provide an immunodiagnostic technology platform that, to our knowledge, has not been previously reported, and prove initial clinical application in a cohort of N = 170, including proof of concept in Multi Cancer Early Detection and personalized medicine.  \nThe idea that the immune system is involved in the surveillance for neoplastic disease originated in the nineteenth century1. While enhancing the immune response to tumour development has become standard-of-care in therapeutics2, detecting the immune response for diagnostic purposes has remained largely unexplored. However, the  \ncentral and general role of tumour immunosurveillance in cancer onset and progression suggests that detecting tumour immunosurveillance for diagnostics could have signiﬁcant potential.  \nInstead, liquid biopsies, which aim to detect cancer presence or prognosis via a non-invasive blood test (Fig. 1a), have become  \nA full list of afﬁliations appears at the end of the paper. e-mail: [cong.tang@gimm.pt](cong.tang@gimm.pt); [luis.costa@ulssm.min-saude.pt](luis.costa@ulssm.min-saude.pt); [emma@proteotype.com](emma@proteotype.com);  \n[gb453@cam.ac.uk](gb453@cam.ac.uk)  \na  \nb  \nMCED  \nimmuno surveillance  \nc.70 mg/mL protein  \nc  \n% of p lasma proteins  \nNormal vs Enhanced immunosurveillance  \nImmunoglobulins IG enhanced  \n Albumin  \n Albumin enhanced  \n Others  \n Others enhanced  \n60  \n45  \n30  \n15  \n0  \nd  \ne  \ntime  \nHost released proteins (xi = 1:3000) Individuals  \nSingle protein x1 target  \nHigh interpatient variation  \nProtein cross section (xi = 1:3000)  \nAvg. cross many protein targets  \nIndividuals  \nLow interpatient variation  \nFig. 1 | Detecting tumour immunosurveillance for diagnostics. aA patient with abreast tumour provides a 5 mL whole blood sample. b The c. 70 mg/mL protein component plays roles in immunosurveillance, in which the immune system identiﬁes and eliminates malignant cells. This process increases in early-stage cancer before cancer immunoediting allows immune escape and metastasis. It is also the target of immunosurveillance increasing drugs, such ","cbCainJzrZ06WOzm","https://ap.wps.com/l/cbCainJzrZ06WOzm","pdf",1193088,14,"English","# Abstract\n## Biomarker panel and immune activation signature\n## Optical measurement in neat plasma\n## Machine-learning detection performance\n## Differential patterns vs autoimmune/infectious disease\n## Predicting cyclin-dependent kinase inhibitor response\n## Clinical validation cohort","[{\"question\":\"What biomarkers are used in the immunodiagnostic platform?\",\"answer\":\"The study measures total concentrations of cysteine and free cysteine, as well as lysine, tryptophan, and tyrosine, which act as protein-incorporated biomarkers reflecting cancer-specific immune activation.\"},{\"question\":\"How well does the platform detect early cancer?\",\"answer\":\"In a validation set of N = 170, the model identifies 78% of cancers with 0% false positives (N = 97) and reports an AUROC of 0.95.\"},{\"question\":\"Can the biomarkers predict treatment response?\",\"answer\":\"Yes. Specific concentration ranges predict response to cyclin-dependent kinase inhibitors in advanced breast cancer patients, identifying 98% of responders (N = 33) with p \\u003c 0.05.\"}]","Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response | PDF",1790177875,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2cf1b6118b1b8600ffb4217b428bf30d.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6357a99ff7a87d583ba01a00ea075a6a.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9f83d5c88b09b9298fa29f8b657aba3b.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b7e92b373795842627af9d20de92637.webp",980,1301]